Recent research has brought to light striking genetic differences in chronic lymphocytic leukemia (CLL) among African American (AA) patients, suggesting that their disease may follow a distinct course compared to European patients. Presented at the SOHO 13th Annual Meeting and published in Clinical Lymphoma, Myeloma, and Leukemia, and reported by Hematology Advisor, the study highlights the need for more inclusive research to improve diagnosis and treatment for all CLL patients.
Lower Rates of Favorable Markers
The investigation focused on 26 African American individuals diagnosed with CLL between 2013 and 2024, analyzing their genetic profiles and comparing the results to established European datasets. A significant discovery was the much lower prevalence of mutated immunoglobulin heavy chain variable (IGHV) genes in AA patients—found in just 19.2%—compared to 56% in Europeans. Since IGHV mutation is associated with milder disease, its rarity in AA patients could point to a tendency toward more aggressive forms of CLL in this group.
Similarly, the commonly favorable deletion of chromosome 13q (del(13q)) was identified in only 42.3% of AA patients, while nearly 70% of Europeans with CLL carry this marker. In contrast, trisomy 12, regarded as an intermediate risk factor, appeared more frequently in the AA cohort (30.8% vs. 12%).
Discovery of Unique and Rare Genetic Changes
The study went beyond common mutations, uncovering rare chromosomal alterations like trisomy 15, trisomy 3, and monosomy 7 exclusively in African American patients. Researchers also detected somatic mutations, such as DNMT3A, NRAS, U2AF1, RUNX1, MYD88, and MALT1 rearrangement, as well as the t(11;14) chromosomal translocation, not observed in the European groups. Interestingly, high-risk TP53 mutations were present at similar rates in both populations.
The Importance of Representation in Genomic Research
Historically, African American patients have been underrepresented in CLL genetic studies, limiting the medical community’s understanding of how the disease manifests and progresses in this population. The authors stress that including more diverse groups in research is essential for developing accurate prognostic models and effective, individualized therapies.
By illuminating these unique genetic patterns, the study makes a compelling case for broadening the scope of future research. Doing so can lead to more precise risk stratification, better informed clinical decisions, and ultimately, improved outcomes for African American patients with CLL.
Looking Forward
This investigation into the genetic landscape of CLL in African Americans demonstrates that one-size-fits-all approaches may not be sufficient. Recognizing and addressing these differences is a critical step toward equity in cancer care. As the field of precision medicine advances, ensuring that all populations are studied and understood will be key to providing the best possible treatment for every patient with CLL.
